Overview

A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
Phase:
Phase 2
Details
Lead Sponsor:
CoLucid Pharmaceuticals
Eli Lilly and Company
Collaborator:
CoLucid Pharmaceuticals
Treatments:
Lasmiditan